Elutia (ELUT) - מכפיל EV/EBITDA
The Elutia Inc. (ELUT) price chart on the GURU.Markets platform demonstrates an EV/EBITDA ratio of 0.00. Elutia Inc. (ELUT) develops innovative bio-implants, including CanGaroo antibacterial envelopes designed to protect pacemakers from infection. The business relies on a niche segment of surgical materials, offsetting risks through demand in orthopedics. Production is based on ESG principles, which include bio-waste recycling and eco-friendly packaging.
פילוחים אנליטיים של חברת elutia.com (ELUT)
The EV/EBITDA multiple determines the total enterprise value of a business relative to its operating profit before interest and taxes, allowing for an assessment of asset efficiency while accounting for debt load. By analyzing the historical EV/EBITDA levels of the company, an investor can determine the degree of business overvaluation, which is critical for Elutia Inc. (ELUT) during the commercialization of its innovative CanGaroo antibacterial matrices and the implementation of FDA-approved medical devices.
